Search
COPD Clinical Trials in Lincoln, NE
A listing of 1 COPD clinical trials in Lincoln, NE actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 1 of 1
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
COPD
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Lincoln, Nebraska, currently has 1 active clinical trials seeking participants for COPD research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
COPD Clinical Research Study
Recruiting
Living with COPD? We are transforming health by bringing clinical trials to you.
Don’t let financial stress hold you back. All pre-screening tests will be provided at no cost to you. See if you pre-qualify and if there is a location that is convenient for you.
Don’t let financial stress hold you back. All pre-screening tests will be provided at no cost to you. See if you pre-qualify and if there is a location that is convenient for you.
Conditions:
COPD
Chronic Obstructive Pulmonary Disease
Pulmonary Disease
Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD)
Featured Trial
Respiratory Syncytial Virus (RSV) Treatment Study
Recruiting
We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Conditions:
RSV
Respiratory Syncytial Virus (RSV)
Healthy
Healthy Volunteers
Healthy Subjects
Featured Trial
Respiratory Syncytial Virus (RSV) Treatment Study
Recruiting
We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Conditions:
RSV
Respiratory Syncytial Virus (RSV)
Healthy
Healthy Volunteers
Healthy Subjects
Featured Trial
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/23/2024
Locations: Research Site, Lincoln, Nebraska
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
1 - 1 of 1